Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Progressive has reported for 9 months of 2023

10/13/23 PGR

Genetico has submitted documents to Rozdravnadzor for Embryotest authorization

10/13/23 GECO

Citigroup reported for 9 months of 2023

10/13/23 C

Sitronics Group bought 25% of the capital of Perm Shipyard

10/13/23 AFKS

Rusagro received a grant to develop an agricultural production management system

10/13/23 RAGR

JPMorgan Chase reported for 9 months of 2023

10/13/23 JPM

Wells Fargo reported for 9 months of 2023

10/13/23 WFC

BlackRock reported for 9 months of 2023

10/13/23 BLK

UnitedHealth reported for 9 months of 2023

10/13/23 UNH

Sitronics Group will introduce the first charging station for electric cars by the end of 2023

10/13/23 AFKS